Literature DB >> 20036951

Biomarkers in neuroendocrine tumors.

Massimiliano Berretta1, Alessandro Cappellani, Maria Di Vita, Salvatore Berretta, Guglielmo Nasti, Alessandra Bearz, Umberto Tirelli, Vincenzo Canzonieri.   

Abstract

Here, we review the role of clinical biomarkers (tissue and circulating markers) in the management of neuroendocrine tumors. These tumors may originate in different organs, from cells embriologically different but expressing common phenotypic characteristics, such as the immuno-reactivity for markers of neuro endocrine differentiation (defined as "pan-neuroendocrine"), the capacity to sec rete specific or aspecific peptide and hormones, and the expression of some receptors, that are at the basis of the current diagnostic and therapeutic approach.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20036951     DOI: 10.2741/s68

Source DB:  PubMed          Journal:  Front Biosci (Schol Ed)        ISSN: 1945-0516


  3 in total

1.  Serum chromogranin A levels for the diagnosis and follow-up of well-differentiated non-functioning neuroendocrine tumors.

Authors:  Yuejuan Cheng; Zhao Sun; Chunmei Bai; Xiaoyan Yan; Ran Qin; Changting Meng; Hongyan Ying
Journal:  Tumour Biol       Date:  2015-09-26

2.  Fatal Systemic Vasoconstriction in a Case of Metastatic Small-Intestinal NET.

Authors:  Jochen Stenzel; Sebastian Noe; Konstantin Holzapfel; Franziska Erlmeier; Florian Eyer
Journal:  Case Rep Gastrointest Med       Date:  2017-07-18

3.  PI3K inhibitor enhances the cytotoxic response to etoposide and cisplatin in a newly established neuroendocrine cervical carcinoma cell line.

Authors:  Zih-Yin Lai; Hsin-Yueh Yeo; Ya-Tse Chen; Kuo-Ming Chang; Tze-Chien Chen; Yung-Jen Chuang; Shing-Jyh Chang
Journal:  Oncotarget       Date:  2017-07-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.